Who Owns Artiva Biotherapeutics Stock?
NASDAQ: ARTVHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 84.78%
- Held by insiders
- 14.97%
- Institutional holders
- 120
- Institutions 84.8%
- Insiders 15.0%
- Public and other 0.2%
Who owns Artiva Biotherapeutics stock?
Institutional investors own about 84.8% of Artiva Biotherapeutics's shares, spread across 120 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 14.97% of ARTV.
The largest institutional holders are RA Capital Management, L.P. (36.32%), Viking Global Investors, L.P. (5.27%) and Blackstone Inc (4.86%). Together, the top 10 institutions control 69.9% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their ARTV positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ARTV
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 17.96M | 36.32% | +82.2% |
| Viking Global Investors, L.P. | 2.60M | 5.27% | +100.0% |
| Blackstone Inc | 2.40M | 4.86% | +100.0% |
| 5AM Venture Management, LLC | 2.35M | 4.76% | 0.0% |
| Venrock Adviser, LLC | 2.04M | 4.13% | +27.0% |
| Franklin Templeton, Inc. | 2.04M | 4.13% | +2.2% |
| Caligan Partners, LP | 1.74M | 3.51% | +100.0% |
| Blackrock Inc. | 1.51M | 3.06% | +117.5% |
| Samsara BioCapital, LLC | 954.86K | 1.93% | +100.0% |
| Vanguard Capital Management LLC | 942.37K | 1.91% | -4.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ARTV
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 699.90K | 1.42% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 542.37K | 1.10% |
| iShares Trust-iShares Russell 2000 ETF | 481.44K | 0.97% |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 456.47K | 0.92% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 269.15K | 0.54% |
| iShares Trust-iShares Russell 2000 Value ETF | 128.55K | 0.26% |
| VANGUARD WELLINGTON FUND-Vanguard U.S. Momentum Factor ETF | 103.72K | 0.21% |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 101.36K | 0.21% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 99.92K | 0.20% |
| iShares Trust-iShares Micro-Cap ETF | 60.80K | 0.12% |
Frequently asked questions
Who is the largest shareholder of Artiva Biotherapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of ARTV, owning 36.32% of shares outstanding (17.96M shares) as of its latest 13F filing.
What percentage of Artiva Biotherapeutics is owned by institutions?
Institutions own about 84.8% of ARTV shares and 99.7% of the public float.
How much of Artiva Biotherapeutics do insiders own?
Insiders, such as officers and directors, own about 14.97% of ARTV shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.